Therapeutic vaccines for cancer: an overview of clinical trials (Q38227030)

31 August 2017

title

Therapeutic vaccines for cancer: an overview of clinical trials (English)

1 reference

31 August 2017

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25001465%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

John Wagstaff

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25001465%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Ignacio Melero, MD-PhD

1

object named as

Ignacio Melero

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25001465%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

4

Christoph Huber

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25001465%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

Winald Gerritsen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25001465%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Giorgio Parmiani

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25001465%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Nicholas Thatcher

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25001465%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Christoph Zielinski

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25001465%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Ian Faulkner

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25001465%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Håkan Mellstedt

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25001465%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Gustav Gaudernack

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25001465%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

language of work or name

English

0 references

publication date

8 July 2014

1 reference

Nature Reviews Clinical Oncology

31 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25001465%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25001465%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25001465%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

509-524

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25001465%20AND%20SRC:MED&resulttype=core&format=json

Cancer vaccines: preclinical studies and novel strategies

11 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Immunological monitoring of anticancer vaccines in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Cancer immunotherapy comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Mining the plasma immunopeptidome for cancer peptides as biomarkers and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Exploiting the mutanome for tumor vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Tumoricidal activity of human dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

What are regulatory T cells (Treg) regulating in cancer and why?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

PD-1 and PD-1 ligands: from discovery to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Harnessing the immune system for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Trial watch: Dendritic cell-based interventions for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Prostate cancer vaccines: Update on clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Vanishing bile duct syndrome arising in a patient with T-cell-rich large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Clinical results of vaccine therapy for cancer: learning from history for improving the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Cancer vaccines: should we be targeting patients with less aggressive disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Immunogenic cell death and DAMPs in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

The secret ally: immunostimulation by anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Chemotherapy ± cetuximab modulates peripheral immune responses in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Systemic effects of local radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

CSF1 expression in nongynecological leiomyosarcoma is associated with increased tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

FMS Kinase Inhibitors: Current Status and Future Prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Potential of CXCR4 antagonists for the treatment of metastatic lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Unique human tumor antigens: immunobiology and use in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Immunological aspects of malignant disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Enhancing adoptive immunotherapy of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients--a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

The tumor-immune microenvironment and response to radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Desirable cell death during anticancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

mTOR regulates memory CD8 T-cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Targeting AKT signaling sensitizes cancer to cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

A methodological framework to enhance the clinical success of cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25– T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.111

Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design.

31 March 2020

1 reference

12 December 2020

Cytokine changes in response to radio-/chemotherapeutic treatment in head and neck cancer

1 reference

12 December 2020

Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host

1 reference

12 December 2020

Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.

1 reference

12 December 2020

Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.

1 reference

12 December 2020

Is colony-stimulating factor-1 a key mediator of breast cancer invasion and metastasis?

1 reference

12 December 2020

The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893.

1 reference

12 December 2020

Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation

1 reference

12 December 2020

Colorectal cancer immunotherapy

1 reference

12 December 2020

Modulation of MHC class II transport and lysosome distribution by macrophage-colony stimulating factor in human dendritic cells derived from monocytes

1 reference

12 December 2020

The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.

1 reference

12 December 2020

10.1038/NRCLINONC.2014.111

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25001465%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

11 June 2020

1044950640

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25001465%20AND%20SRC:MED&resulttype=core&format=json